Group 1: R&D Investment and Strategy - The company plans to continue increasing R&D investment, focusing on key product areas and AI strategic layout [1] - A complete R&D pipeline is in place, with budget decisions based on mid-to-long-term strategies [1] - The company has accumulated 26 years of clinical experience, aiming to develop medical-grade wearable devices [2] Group 2: Revenue Growth and Market Expansion - Future growth points include respiratory therapy, blood glucose management, POCT, home health monitoring, and emergency care, with an active expansion into overseas markets [2] - The company achieved a total revenue of CNY 75.66 billion and a net profit of CNY 18.06 billion in 2024 [8] - In Q1 2025, the company reported a revenue of CNY 24.36 billion and a net profit of CNY 6.25 billion [8] Group 3: Competitive Positioning and Market Challenges - The company faces competition from major players like Abbott in the CGM market, with a current market share that is expected to grow [11] - The overseas business has seen a 30% revenue increase, primarily driven by regions like Southeast Asia, Europe, and South America [11] - The company is monitoring the impact of high tariffs in the U.S. on its overseas business and is developing risk management strategies [11] Group 4: Brand and Market Perception - The company emphasizes the importance of brand strength, product quality, and service in enhancing its market position [4] - The company’s goodwill stands at CNY 1.107 billion, accounting for less than 7% of total assets, indicating manageable impairment risks [4] Group 5: Future Outlook and Goals - The company aims to be among the top three in the global home healthcare market, with current contributions from home customers being evaluated [3] - The company is committed to long-term strategies and organic growth, alongside potential acquisitions to drive business expansion [6] - The company acknowledges that its current P/E ratio is undervalued, which may affect market perception [10]

安徽建工集团股份有限公司 安徽建工集团股份有限公司 2024 年年度股东大会会议资料 目 录 议案五、2024 年度公司财务决算及 2025 年度财务预算报告 ......... 34 议案七、关于提请股东大会授权董事会制定 2025 年度中期利润分配方案 议案八、关于确认董事 2024 年度薪酬及 2025 年度薪酬方案的议案... 41 议案九、关于确认监事 2024 年度薪酬及 2025 年度薪酬方案的议案... 42 安徽建工集团股份有限公司 2024 年年度股东大会会议资料 一、时间：2025 年 5 月 16 日上午 9:00 二、地点：合肥市黄山路 459 号安建国际大厦公司会议室 三、议程： 合的方式。网络投票起止时间：自 2025 年 5 月 16 日至 2025 年 5 月 16 日， 现场会议开始时间为 2025 年 5 月 16 日上午 9:00。 本次股东大会采用上海证券交易所网络投票系统，通过交 易系统投票平台的投票时间为股东大会召开当日的交易时间 段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联网投 票平台的投票时间为股东大会召开当日的 9:15 ...

煤炭 优于大市（维持） 证券分析师 翟堃 资格编号：s0120523050002 邮箱：zhaikun＠tebon.com.cn 研究助理 谢佶圆 邮箱：xiejy＠tebon.com.cn 市场表现 -34% -26% -17% -9% 0% 9% 17% 26% 2024-05 2024-09 2025-01 煤炭开采 沪深300 资料来源：聚源数据、德邦研究所 相关研究 1.《永泰能源（600157.SH）：煤炭 主业以量补价，煤电协同稳步推 进》，2025.4.29 2.《煤炭周报：宏观预期强化，重 视板块底部布局》，2025.4.27 3.《煤炭周报：煤价震荡寻底，关 注板块红利属性》，2025.4.20 4.《煤炭行业月报：3 月进口同比转 负 ， 静 待 后 续 需 求 改 善 》， 2025.4.18 5.《煤炭周报：煤价底部企稳，回 购增持彰显板块价值》，2025.4.12 煤炭开采 2025 年 05 月 11 日 请务必阅读正文之后的信息披露和法律声明 证券研究报告 | 行业周报 25Q1 业绩同环比下滑，寻找相对确定性投资机会。据 CCTD 中国煤炭市场网， 2024 年煤炭全行业实现 ...

如何以提高上市公司发展质量为抓手，全力培育和打造一批经营业绩佳、创新能力强、治理体系优、市场认可 度高的一流上市公司？ 5月9日，上海市国资委联合上海证券交易所，共同举办了上海国有控股上市公司2024年度集体业绩说明会，以 推动上海市国有控股上市公司在做强做优做大、提升内在价值的同时，进一步强化投资者关系管理、提高信息 透明度、增进市场认同。 本次业绩说明会上，上港集团、华谊集团、上海医药、浦发银行、中国太保、数据港等6家在上交所挂牌的上 海国有控股上市公司，全方位展示了各自在经营发展、产业布局、技术创新、ESG建设、投资者回报等方面的 成效与未来规划。 近年来，上海市国资委持续加强上海市国有控股上市公司市值管理工作，通过强化政策引领、实施重点领域资 本运作项目、加速国资基金设立及运作、稳妥开展风险防范和处置等举措，助推上市公司提质增效，稳步提升 经营效率和盈利能力。截至2024年末，上海市94家国有控股上市公司总市值2.78万亿元，较年初增加6177.74亿 元，增长28.52%。 今年是"十四五"规划和国企改革深化提升行动的"双收官"之年，也是"十五五"谋篇布局之年。上海市国资委表 示，下一步，上海国资国 ...

Group 1: Core Insights - The Shanghai Municipal State-owned Assets Supervision and Administration Commission and the Shanghai Stock Exchange held a performance briefing to enhance the quality of state-owned listed companies and strengthen investor relations [1][2] - The total market value of 94 state-owned listed companies in Shanghai reached 2.78 trillion yuan, an increase of 617.77 billion yuan or 28.52% from the beginning of the year [1] Group 2: Company Highlights - Shanghai Port Group achieved a container throughput of 51.51 million TEUs, a year-on-year increase of 4.8%, maintaining its position as the world's largest port for 15 consecutive years [3] - Shanghai Port Group's net profit attributable to shareholders reached 14.95 billion yuan, a 13.3% increase year-on-year [3] - Huayi Group reported a revenue of 44.6 billion yuan, a 9.3% increase, and a net profit of 910 million yuan, up 5.8% [5][6] - Shanghai Pharmaceutical achieved a revenue of 275.25 billion yuan, a 5.75% increase, and a net profit of 4.55 billion yuan, a 20.82% increase [8][9] - Pudong Development Bank's net profit reached 45.3 billion yuan, a 23.31% increase, marking the highest growth in nearly 12 years [10][11] - China Pacific Insurance Group reported a revenue of 404.09 billion yuan, a 24.7% increase, and a net profit of 44.96 billion yuan, a 64.9% increase [13][14] - DataPort achieved a revenue of approximately 1.72 billion yuan, an 11.57% increase, and a net profit of approximately 132 million yuan, a 7.49% increase [15][16] Group 3: Strategic Initiatives - Shanghai Port Group is focusing on digital, intelligent, and green transformation to enhance its core business and sustainable development capabilities [3][4] - Huayi Group is advancing major technological projects and has filed 151 patents, with 134 granted [6][7] - Shanghai Pharmaceutical is optimizing its R&D system and has established a new innovation center to accelerate the development of a collaborative ecosystem [8][9] - Pudong Development Bank is implementing a digital finance strategy and enhancing its service efficiency through various digital platforms [10][11] - China Pacific Insurance is expanding its green insurance offerings and enhancing its technology-driven services [13][14] - DataPort is deepening its IDC service capabilities and has been recognized as a top service provider in the industry [15][16]

2025年05月09日，福安药业2024年度业绩网上说明会在全景网顺利举行。出席本次业绩说明会的人员有 董事长汪天祥、董秘汤沁、财务负责人余雪松、独立董事陈耿。 根据全景数据后台统计，在今天的交流过程中，来自全国多个省、市地区的投资者共向上市公司提问47 个，公司嘉宾共回答问题47个，答复率100.00%，充分实现了上市公司与投资者的良好互动。 以下为业绩说明会问答实录： 回答：你好，公司2024年合并的营业收入为23.91亿元、合并成本11.25亿元。公司未来会在全产业链的 基础上，加大对非集采产品的市场拓展力度，充分发挥公司丰富的产品结构优势，提升收入；同时结合 公司逐步投产的新的智能化厂区，节能增效优化成本。 4、问：请问去年福安药业股吧里曾几度出现署名"汪天祥"的发言，那是您吗？【征集问题】 回答：本人从未在股吧发表过任何言论，股吧并非官方信息披露媒体，提醒投资者应注意对有关信息进 行理性甄别，谢谢！ 5、问：请问福安药业的市值维护有那些举措？【征集问题】 回答：公司将立足提升公司质量，依法依规运用各类方式提升公司投资价值，包括提升经营业绩，持续 现金分红，加强投资者关系管理，提高信息披露质量等多种举 ...

上海市国资委以提高上市公司发展质量为抓手，全力培育和打造一批经营业绩佳、创新能力强、治理体系优、市场认可度高的一流上市公司。其中，上港集 团母港集装箱吞吐量连续15年保持世界首位，上海港成为全球首个年集装箱吞吐量超过5000万标准箱的世界大港。2024年，上港集团港口能力建设扎实推 进，罗泾港区改造一期工程实现开港运营，罗泾港区改造二期工程获得核准批复，小洋山北侧工程建设按节点目标扎实推进。 5月9日，上海市国资委联合上海证券交易所举办上海国有控股上市公司2024年度集体业绩说明会，旨在推动上海国有控股上市公司进一步强化投资者关系管 理、增进市场认同，提升内在价值。上港集团（600018）、华谊集团（600623）、上海医药（601607）、浦发银行、中国太保（601601）、数据港 （603881）等6家在上交所挂牌的上海国有控股上市公司参加本次业绩说明会。 上港集团副总裁、董事会秘书、总法律顾问丁向明表示："进入4月份，尽管公司在美国的航线业务量出现了一定波动，但从4月份集装箱吞吐量来看，同比 仍有所增长。"他同时透露，公司将加强动态数据趋势监控，积极推进业务模式创新，深化在长三角港口群的协同效应，通过创 ...

Core Viewpoint - Jiangsu Jinshiyuan Liquor Co., Ltd. reported significant growth in key financial metrics for 2024, including a 14.31% increase in total revenue and an 8.80% rise in net profit attributable to shareholders, reflecting the company's commitment to high-quality development and strategic management [3][19]. Meeting Information - The annual shareholders' meeting is scheduled for May 21, 2025, with a combination of on-site and online voting [2][3]. - The meeting will include reports from the board of directors and the supervisory board, as well as discussions on various proposals [1][12]. Financial Performance - Total revenue for 2024 reached 115.46 billion yuan, a 14.31% increase from the previous year [3][19]. - Net profit attributable to shareholders was 34.12 billion yuan, marking an 8.80% year-on-year growth [3][19]. - The company achieved a total asset value of 242.22 billion yuan, up 11.98% from the previous year [21][22]. Governance and Compliance - The board of directors conducted seven meetings in 2024, adhering to legal and regulatory requirements, and ensuring transparency in decision-making [4][9]. - The supervisory board held four meetings, focusing on compliance and the protection of shareholder rights, with no violations reported [13][15]. Strategic Initiatives - The company aims to enhance its ESG (Environmental, Social, and Governance) ratings, achieving a notable improvement in MSCI ratings and ranking among the top three in domestic ESG ratings for liquor companies [7][8]. - The board plans to focus on sustainable development and strategic resource allocation to ensure long-term growth and stability [11][12]. Shareholder Engagement - The company has established multiple channels for investor communication, including performance briefings and investor meetings, to enhance transparency and engagement [10][11]. - In 2024, the company received recognition for its investor relations management, further solidifying its commitment to shareholder engagement [10][11].

Core Viewpoint - Harbin Fulejia Technology Co., Ltd. is demonstrating resilience and potential in the competitive medical beauty skincare market, focusing on precise consumer demand and diversified market expansion [2] Group 1: Market Performance - In 2024, Fulejia achieved operating revenue of 2.017 billion yuan, a year-on-year increase of 4.32% [2] - Online sales reached 1.108 billion yuan in 2024, growing by 20.03% year-on-year, with strong performance during promotional events [3] Group 2: R&D and Innovation - R&D expenses increased by 6.04% in 2024, with the number of R&D personnel growing by 114.81% [3] - The completion of a self-owned production base and the establishment of a Shanghai R&D center in 2024 signify a strengthened R&D capability [3] Group 3: Shareholder Returns and Strategic Adjustments - Fulejia announced its first dividend in May 2024, with plans for another before the Spring Festival in early 2025, aiming to enhance stock liquidity [4] - The company is optimizing sales channel structures and strengthening product pricing management for long-term sustainable development [4][5] Group 4: Competitive Advantage - The acquisition of Harbin Beixing Pharmaceutical Co., Ltd. has provided Fulejia with independent production capabilities, laying a solid foundation for long-term growth [5] - The company aims to leverage its comprehensive competitive advantages in R&D, products, branding, resources, and market to enhance its position in the medical beauty skincare sector [5]

证券代码：300784 证券简称：利安科技 宁波利安科技股份有限公司投资者关系活动记录表 编号：20250509 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 现场参观 □其他 参会单位名称及人 员姓名 投资者网上提问 时间 2025 年 5 月 9 日 15:30-17:00 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网络远程的方式召 开业绩说明会 上市公司接待人员 1、董事长：李士峰先生 2、董事、总经理：邱翌女士 3、董事、董事会秘书、副总经理：陈军先生 4、独立董事：高金波先生 5、财务总监：叶奇山先生 6、保荐代表人：罗云翔先生 投资者关系活动主 要内容介绍 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、领导，您好！我来自四川大决策 麻烦介绍一下公司"宁波利安科技股份有 限公司消费电子注塑件扩产项目"和"宁波利安科技股份有限公司滨海项目"的进 展情况？ 答：感谢您对公司的关注！"宁波利安科技股份有限公司消费电子注塑件扩产 项目"和"宁波利安科技股份有限公司滨海 ...